stockportfolio.pro
Stocks / RPRX vs RVMD
RPRX vs RVMD
Royalty Pharma plc and Revolution Medicines, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Royalty Pharma plc (RPRX) | Revolution Medicines, Inc. (RVMD) | |
|---|---|---|
| Market cap | $31.6B | $31.3B |
| Revenue (latest FY) | $2.38B | $0 |
| Net income (latest FY) | $770.95M | $-1.13B |
| Revenue growth (5y CAGR) | 2.3% | — |
| Net margin | 32.4% | — |
| Return on equity | 11.9% | -69.3% |
| P/E ratio | 28.9 | — |
| Dividend yield | 1.7% | — |
| Profitable years (of last 10) | 8 | 0 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RPRX — free Open RVMD — freeFrequently asked questions
Which is bigger, RPRX or RVMD?
Royalty Pharma plc is larger by market capitalization — $31.6B versus $31.3B.
Which grows faster, RPRX or RVMD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.